Cassipa sublingual film for opioid dependenceOctober 10, 2018
The US FDA granted approval to Teva to market Cassipa (buprenorphine and naloxone) sublingual film for the maintenance treatment of opioid dependence.
“We’ve taken a number of steps to advance the development of new FDA-approved treatments for opioid dependence and encourage health care professionals to ensure patients are offered an adequate chance to benefit from these therapies,” said FDA Commissioner Scott Gottlieb, M.D.
Opioid use disorder should be viewed similarly to any other chronic condition that is treated with medication, he added.
Medication-assisted treatment (MAT) is a comprehensive approach that combines FDA-approved medications (currently methadone, buprenorphine, or naltrexone) with counseling and other behavioural therapies to treat patients with opioid use disorder (OUD).
Regular adherence to MAT with buprenorphine reduces opioid withdrawal symptoms and the desire to use opioids, without causing the cycle of highs and lows associated with opioid misuse or abuse. At proper doses, buprenorphine also decreases the pleasurable effects of other opioids, making continued opioid abuse less attractive.
According to the Substance Abuse and Mental Health Services Administration, patients receiving MAT for treatment of their OUD cut their risk of death from all causes in half, according to an FDA release.
In June, the FDA also approved the first generic versions of Suboxone (buprenorphine and naloxone) sublingual film in multiple strengths.